Literature DB >> 11782258

Tolerance and near-tolerance strategies in monkeys and their application to human renal transplantation.

S J Knechtle1, M M Hamawy, H Hu, J H Fechner, C S Cho.   

Abstract

Studies in non-human primates to evaluate tolerance strategies in organ transplantation have led to innovation in human transplantation. The two strategies we have studied in detail in non-human primates are T-cell depletion by anti-CD3 immunotoxin and co-stimulation blockade. Each of these strategies has been extended into early human trials in renal transplantation. The results of these human and non-human primate studies are summarized. Continued progress in better and safer immunosuppressive methods remains closely linked to research using non-human primates. However, there has not been a one-to-one correspondence between efficacy in the primate and efficacy in humans. Rather, principles can be derived from non-human primate studies that can be extended into human trials with the knowledge that regimens will likely differ in humans compared to non-human primates.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11782258     DOI: 10.1034/j.1600-065x.2001.1830116.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  4 in total

1.  Prevention trumps treatment of antibody-mediated transplant rejection.

Authors:  Stuart J Knechtle; Jean Kwun; Neal Iwakoshi
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

2.  Fates of CD4+ T cells in a tolerant environment depend on timing and place of antigen exposure.

Authors:  B E Burrell; J S Bromberg
Journal:  Am J Transplant       Date:  2011-12-17       Impact factor: 8.086

3.  Linked sensitization by memory CD4+ T cells prevents costimulation blockade-induced transplantation tolerance.

Authors:  Michael S Andrade; James S Young; Jared M Pollard; Dengping Yin; Maria-Luisa Alegre; Anita S Chong
Journal:  JCI Insight       Date:  2022-06-08

4.  Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects.

Authors:  K Okimura; K Maeta; N Kobayashi; M Goto; N Kano; T Ishihara; T Ishikawa; H Tsumura; A Ueno; Y Miyao; S Sakuma; F Kinugasa; N Takahashi; T Miura
Journal:  Am J Transplant       Date:  2014-04-14       Impact factor: 8.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.